These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 35475361

  • 1. A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (Journal of Psychopharmacology, 2021, Vol. 35(8) 890-900).
    Terao I, Honyashiki M, Inoue T.
    J Psychopharmacol; 2022 May; 36(5):653-654. PubMed ID: 35475361
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
    Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ.
    J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
    [Abstract] [Full Text] [Related]

  • 3. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M, Bartova L, Kasper S.
    Int J Neuropsychopharmacol; 2020 Jul 29; 23(7):440-445. PubMed ID: 32570275
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y.
    BMC Psychiatry; 2021 Oct 25; 21(1):526. PubMed ID: 34696742
    [Abstract] [Full Text] [Related]

  • 6. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M, Bartova L, Kautzky A, Serretti A, Porcelli S, Souery D, Mendlewicz J, Montgomery S, Zohar J, Kasper S.
    Eur Neuropsychopharmacol; 2018 Dec 25; 28(12):1305-1313. PubMed ID: 30446357
    [Abstract] [Full Text] [Related]

  • 7. Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
    Lengvenyte A, Strumila R, Olié E, Courtet P.
    Eur Neuropsychopharmacol; 2022 Apr 25; 57():88-104. PubMed ID: 35219097
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC.
    JAMA Psychiatry; 2018 Feb 01; 75(2):139-148. PubMed ID: 29282469
    [Abstract] [Full Text] [Related]

  • 9. Geriatric psychopharmacology.
    Pies R.
    Am Fam Physician; 1983 Oct 01; 28(4):171-6. PubMed ID: 6139001
    [Abstract] [Full Text] [Related]

  • 10. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
    Morlet E, Costemale-Lacoste JF, Poulet E, McMahon K, Hoertel N, Limosin F, CSA Study Group.
    J Affect Disord; 2019 Dec 01; 259():210-217. PubMed ID: 31446382
    [Abstract] [Full Text] [Related]

  • 11. Comments to Drs. Bahji, Vazquez, and Zarate.
    Drevets WC, Popova V, Daly EJ, Borentain S, Lane R, Cepeda MS, Mathews M, Manji HK, Canuso CM.
    J Affect Disord; 2021 Mar 15; 283():262-264. PubMed ID: 33571795
    [Abstract] [Full Text] [Related]

  • 12. Treatment of bipolar depression: making sensible decisions.
    Citrome L.
    CNS Spectr; 2014 Dec 15; 19 Suppl 1():4-11; quiz 1-3, 12. PubMed ID: 25407667
    [Abstract] [Full Text] [Related]

  • 13. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.
    Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R.
    Gen Hosp Psychiatry; 2018 Dec 15; 54():62-64. PubMed ID: 30100209
    [No Abstract] [Full Text] [Related]

  • 14. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.
    Encephale; 2004 Dec 15; 30(5):417-24. PubMed ID: 15627046
    [Abstract] [Full Text] [Related]

  • 15. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.
    Kato M, Chang CM.
    CNS Drugs; 2013 May 15; 27 Suppl 1():S11-9. PubMed ID: 23709358
    [Abstract] [Full Text] [Related]

  • 16. "Novel Psychopharmacology for Depressive Disorders".
    Fornaro M, De Berardis D, Anastasia A, Fusco A.
    Adv Exp Med Biol; 2021 May 15; 1305():449-461. PubMed ID: 33834412
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J, Kawalec P, Pilc A.
    Expert Opin Pharmacother; 2020 Jan 15; 21(1):9-20. PubMed ID: 31663783
    [Abstract] [Full Text] [Related]

  • 18. A half-century of participant observation in psychiatry. Part III: psychopharmacology.
    Rybakowski J.
    Psychiatr Pol; 2020 Oct 31; 54(5):845-864. PubMed ID: 33529273
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB.
    JAMA Psychiatry; 2019 Sep 01; 76(9):893-903. PubMed ID: 31166571
    [Abstract] [Full Text] [Related]

  • 20. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.
    DeBattista C, DeBattista K.
    Curr Drug Saf; 2010 Jul 02; 5(3):263-6. PubMed ID: 20394571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.